Patents Assigned to MEDIGEN VACCINE BIOLOGICS CORPORATION
  • CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230110516
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: April 13, 2023
    Applicants: Dynavax Technologies Corporation, MEDIGEN VACCINE BIOLOGICS CORPORATION
    Inventors: John D. CAMPBELL, Robert S. JANSSEN, David NOVACK, Tsun-Yung KUO, Charles CHEN, Chung-Chin WU, Yi-Jiun LIN, Meei-Yun LIN, Yu-Chi WU